Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:Q8TEW0 (
Par3
)
364
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Maintenance of single-layered endothelium, squamous endothelial cell shape, and formation of a patent vascular lumen all require defined endothelial cell polarity. Loss of beta1 integrin (Itgb1) in nascent endothelium leads to disruption of arterial endothelial cell polarity and lumen formation. The loss of polarity is manifested as cuboidal-shaped endothelial cells with dysregulated levels and mislocalization of normally polarized cell-cell adhesion molecules, as well as decreased expression of the polarity gene
Par3
(pard3). beta1 integrin and
Par3
are both localized to the endothelial layer, with preferential expression of
Par3
in arterial endothelium.
Luminal
occlusion is also exclusively noted in arteries, and is partially rescued by replacement of
Par3
protein in beta1-deficient vessels. Combined, our findings demonstrate that beta1 integrin functions upstream of
Par3
as part of a molecular cascade required for endothelial cell polarity and lumen formation.
...
PMID:Beta1 integrin establishes endothelial cell polarity and arteriolar lumen formation via a Par3-dependent mechanism. 2015 76
